Abilify Maintena® 960 mg (aripiprazole) approved in the

Aripiprazole’s new long-acting injectable (LAI) formulation enables continuous exposure to medication for two months1.Windsor, United Kingdom/Valby, Denmark, 27 March, 2024 – Otsuka Pharmaceutical Europe Ltd. (Otsuka) and H. Lundbeck A/S (Lundbeck) today announced that the European Commission (EC) has ap...

Related Keywords

Valby , Hovedstaden , Denmark , Tokyo , Japan , Liechtenstein , Norway , Iceland , Abilify Maintena , Peter Gillberg , Otsuka Europe , Johan Luthman , European Commission , Otsuka Pharmaceutical Company Ltd , Otsuka Holdings Co Ltd , Head Of Medical Affairs At Otsuka Europe , European Union , Otsuka Pharmaceutical Europe Ltd , Head Of Research Development At Lundbeck , Otsuka Pharmaceutical Europe , Executive Vice President , Vice President , Medical Affairs , Pharmaceutical Europe , Otsuka Pharmaceutical Company ,